今年以来港股创新药的强势行情被引爆,随着中报窗口期临近,多家外资投行纷纷发布研报,继续看多港股创新药板块,上调相关公司评级。大摩、美银、花期、瑞银等近期均上调了中国生物制药评级及目标价,瑞银8月7日将其目标价调升至11.7港元,按8月11日最新收盘价计算,还有50%以上的上涨空间。近日招银国际研报首次覆盖该公司,也给出“买入”评级及9.4港元的目标价。随着中国创新疗法不断取得突破,今年相关创新药...
Source Link今年以来港股创新药的强势行情被引爆,随着中报窗口期临近,多家外资投行纷纷发布研报,继续看多港股创新药板块,上调相关公司评级。大摩、美银、花期、瑞银等近期均上调了中国生物制药评级及目标价,瑞银8月7日将其目标价调升至11.7港元,按8月11日最新收盘价计算,还有50%以上的上涨空间。近日招银国际研报首次覆盖该公司,也给出“买入”评级及9.4港元的目标价。随着中国创新疗法不断取得突破,今年相关创新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.